美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Dova Pharmaceuticals Inc.

28.04

0.0000

成交量：- -

成交额：- -

市值：8.08亿

市盈率：-10.95

高：28.04

开：28.04

低：28.04

收：28.04

52周最高：28.54

52周最低：5.62

股本：2,880.19万

流通股本：933.84万

量比：- -

换手率：- -

股息：- -

股息率：- -

每股收益(TTM):-2.5607

每股收益(LYR):-2.5998

净资产收益率：-90.08%

总资产收益率：-39.36%

市净率：15.90

市盈率(LYR):-10.79

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

Dova Pharmaceuticals Inc.

交易所：

NASDAQ

成立时间：

- -

员工人数：

- -

公司地址：

- -

官网：

http://www.dova.com

邮编：

- -

电话：

- -

传真：

- -

简介：

Dova制药有限公司最初以PBM AKX Holdings，LLC命名成立，是一家根据特拉华州法律于2016年3月24日成立的有限责任公司。该公司是一家专注于获得，开发和商业化专业医生治疗疾病的候选药物的制药公司，最初的重点是解决血小板减少症，一种以低血小板计数为特征的疾病。他们从Eisai，Inc.或Eisai于2016年3月获得的候选药物avatrombopag是口服血小板生成素受体激动剂或TPO-RA，它们正在开发用于治疗血小板减少症。该公司最近完成了两项相同设计的关键的3期临床试验，该临床试验评估了avatrombopag用于治疗慢性肝病或CLD患者的血小板减少症，其经历了不发生于微创至中等程度的微创医疗程序。 Avatrombopag在这些具有高统计学意义的临床试验中遇到主要和次要终点。根据这些结果，计划在2017年第三季度向美国食品和药物管理局（FDA）提交新的药物申请或NDA，以提供初步指示。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/DOVA/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DOVA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DOVA\",,,,,undefined,":{"symbol":"DOVA","market":"US","secType":"STK","nameCN":"Dova Pharmaceuticals Inc.","latestPrice":28.04,"timestamp":1573506000000,"preClose":28.04,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":9338364,"shares":28801863,"eps":-2.560714,"marketStatus":"停牌","change":0,"latestTime":"02-24 15:57:34 EST","open":28.04,"high":28.04,"low":28.04,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.560714,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1771966800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1498708800000,"exchange":"NASDAQ","adjPreClose":28.04,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DOVA\",,,,,undefined,":{"symbol":"DOVA","floatShares":9338364,"roa":"-39.36%","roe":"-90.08%","lyrEps":-2.599775,"shares":28801863,"dividePrice":0,"high":28.04,"amplitude":0,"preClose":28.04,"low":28.04,"week52Low":5.62,"pbRate":"15.90","week52High":28.54,"institutionHeld":0,"latestPrice":28.04,"eps":-2.560714,"divideRate":0,"volume":0,"delay":0,"ttmEps":-2.560714,"open":28.04,"prevYearClose":28.04},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DOVA\",params:#limit:5,,,undefined,":[{"date":"2019-08-06","symbol":"DOVA","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2019/06","expectedEps":-0.57,"defaultRemindTime":1565078400000,"name":null,"time":"盘前","dateTimestamp":1565064000000,"actualEps":-0.7},{"market":"US","date":"2019-03-05","symbol":"DOVA","fiscalQuarterEnding":"2018/12","expectedEps":-0.77,"name":null,"time":"盘前","type":"earning","dateTimestamp":1551762000000,"reportTimeType":"pre","actualEps":-0.69},{"market":"US","date":"2018-11-08","symbol":"DOVA","fiscalQuarterEnding":"2018/09","expectedEps":-0.82,"name":null,"time":"盘后","type":"earning","dateTimestamp":1541653200000,"reportTimeType":"post","actualEps":-0.69},{"market":"US","date":"2018-08-09","symbol":"DOVA","fiscalQuarterEnding":"2018/06","expectedEps":-0.58,"name":null,"time":"盘后","type":"earning","dateTimestamp":1533787200000,"reportTimeType":"post","actualEps":-0.7},{"market":"US","date":"2018-05-09","symbol":"DOVA","fiscalQuarterEnding":"2018/03","expectedEps":-0.45,"name":null,"time":"盘后","type":"earning","dateTimestamp":1525838400000,"reportTimeType":"post","actualEps":-0.52}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DOVA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DOVA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.dova.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0009},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0109},{"period":"6month","weight":0.0553},{"period":"1year","weight":0.1374},{"period":"ytd","weight":0.0007}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Dova制药有限公司最初以PBM AKX Holdings，LLC命名成立，是一家根据特拉华州法律于2016年3月24日成立的有限责任公司。该公司是一家专注于获得，开发和商业化专业医生治疗疾病的候选药物的制药公司，最初的重点是解决血小板减少症，一种以低血小板计数为特征的疾病。他们从Eisai，Inc.或Eisai于2016年3月获得的候选药物avatrombopag是口服血小板生成素受体激动剂或TPO-RA，它们正在开发用于治疗血小板减少症。该公司最近完成了两项相同设计的关键的3期临床试验，该临床试验评估了avatrombopag用于治疗慢性肝病或CLD患者的血小板减少症，其经历了不发生于微创至中等程度的微创医疗程序。 Avatrombopag在这些具有高统计学意义的临床试验中遇到主要和次要终点。根据这些结果，计划在2017年第三季度向美国食品和药物管理局（FDA）提交新的药物申请或NDA，以提供初步指示。","exchange":"NASDAQ","name":"Dova Pharmaceuticals Inc.","nameEN":"Dova Pharmaceuticals Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"DOVA\",market:\"US\",,,undefined,":null}}